A Systematic Review of the Gastrointestinal Microbiome: A Game Changer in Colorectal Cancer

Eastmond, Aziza K; Shetty, Chaitra; Rizvi, Syed Muhammad Hannan Ali; Sharaf, Joudi; Williams, Kerry-Ann D; Tariq, Maha; Acharekar, Maitri V; Saldivia, Sara Elena Guerrero; Unnikrishnan, Sumedha; Chavarria, Yeny Y; Akindele, Adebisi O; Jalkh, Ana P; Balani, Prachi

doi:10.7759/cureus.28545

Cited by 5 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of the 96 reports that were selected for full-text review, 22 of them were not obtainable. We assessed the eligibility of all 74 articles and identified only 20 systematic reviews and meta-analyses that met our inclusion criteria for the final synthesis [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Figure 1 represents the PRISMA flow diagram with a detailed search and selection process overview.…”

Section: Search Resultsmentioning

confidence: 99%

“…FIGURE 2: Matrix heatmap of included reviewsAlhhazmi et al[12]; Amitay et al[13]; Anandakumar et al[14]; Aprile et al[15]; Borges-Canha et al[16]; Costa et al[17]; Eastmond et al[18]; Fratila et al[19]; Gethings-Behncke et al[20]; Hussan et al[21]; Karimi et al[22]; Mohammad et al[23]; Negrut et al[24]; Peng et al[25]; Ranjbar et al[26]; Tabowei et al[27]; Valciukiene et al[28]; Vorstenbosch et al[29]; Yu et al[30]; Zwezerijnen-Jiwa et al[31] …”

mentioning

confidence: 99%

See 1 more Smart Citation

Gut Microbiota and Colorectal Cancer: An Umbrella Review of Methodological Trends and Clinical Correlations

Kasagga,

Hawrami,

Ricci

et al. 2024

Cureus

View full text Add to dashboard Cite

In this umbrella review, we analyze the effect of gut microbiota on the development and progression of colorectal cancer (CRC), a global health challenge. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines, we searched multiple databases for the most relevant systematic reviews and meta-analyses from 2000 to 2023. We identified 20 articles that met our inclusion criteria. The findings include the identification of specific microbiota markers, such as Fusobacterium nucleatum, for potential early diagnosis and improvement of disease treatment. This thorough study not only establishes the connection between microbiota and CRC but also provides valuable knowledge for future research in developing microbiome-centered treatments and preventive methods.

show abstract

Section: Search Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Gut Microbiota and Colorectal Cancer: An Umbrella Review of Methodological Trends and Clinical Correlations

Kasagga,

Hawrami,

Ricci

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…ETFB and polyketide synthase positive (pks+) E. coli have also been associated with colorectal cancer development [155][156][157]. These bacteria induce DNA damage by producing colibactin and the B. fragilis toxin (BFT), respectively [158][159][160][161].…”

Section: Digestive Cancers and The Microbiotamentioning

confidence: 99%

Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers

Profir,

Roşu,

Creţoiu

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Digestive cancers are among the leading causes of cancer death in the world. However, the mechanisms of cancer development and progression are not fully understood. Accumulating evidence in recent years pointing to the bidirectional interactions between gut dysbiosis and the development of a specific type of gastrointestinal cancer is shedding light on the importance of this “unseen organ”—the microbiota. This review focuses on the local role of the gut microbiota imbalance in different digestive tract organs and annexes related to the carcinogenic mechanisms. Microbiota modulation, either by probiotic administration or by dietary changes, plays an important role in the future therapies of various digestive cancers.

show abstract

“…In consideration of the fact that, as highlighted, the metabolic disorders that correlate with the incidence and progression of tumors are often associated with conditions of dysbiosis of the microbiota, it is understandable that an effective preventive or therapeutic treatment cannot be separated from the control of this variable. We have seen how numerous and important scenarios induced by alterations to the bacteria of the gut microbiota are able to interfere with various pathophysiological processes that lead to the formation and progression of numerous pathologies, including tumors [ 28 , 29 , 30 , 31 , 32 ], and consequently, it is no longer acceptable to disregard any possible ways to improve our ability to modulate this scenario as well [ 33 ].…”

Section: Possibility Of Intervention Treatment Of Metabolic Disorders...mentioning

confidence: 99%

Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis

Cazzaniga

Zonzini

Pierro

et al. 2022

IJMS

View full text Add to dashboard Cite

Metabolic disorders, mainly characterized as the marked alteration of the lipid and carbohydrate profile, in addition to the clinical presence of the direct consequences of these alterations, are pathological conditions that have considerably increased in prevalence in recent years. They are directly linked to the onset of various pathologies, including cancer, particularly breast cancer, and are hormone-responsive. Alongside the known conditions responsible for this scenario, such as nutrition and lifestyle in general, the importance of both the colonic microbiota and the various organs and systems is becoming increasingly evident. In fact, it is now evident that microbial dysbiosis plays a fundamental role in the onset of these metabolic disorders, and therefore how these conditions are indirectly responsible for the onset and progression of neoplasms. Indirect mechanisms such as an altered Firmicutes/Bacteroidetes ratio; the formation of metabolites such as short-chain fatty acids (SCFAs), in particular, butyrate, which is capable of acting as a tumor suppressor; and the glucuronidase activity of estroboloma (bacteria responsible for estrogen metabolism) are just some of the most important mechanisms that contribute to the history of breast cancer. It is therefore understandable that in clinical terms, it is essential to associate the modulation of metabolic disorders and the microbial conditions that contribute to generating them with common therapies, preferably using compounds and solutions that are effective and acceptable for the patient without side effects. Nutraceuticals such as berberine (active both in metabolic scenarios and in the microbiota) and interventions modulating the microbial structure such as the use of probiotics and prebiotics seem to be ideal solutions for these preventive and no-longer-ignorable strategies in the light of numerous data now present in the literature.

show abstract

A Systematic Review of the Gastrointestinal Microbiome: A Game Changer in Colorectal Cancer

Cited by 5 publications

References 16 publications

Gut Microbiota and Colorectal Cancer: An Umbrella Review of Methodological Trends and Clinical Correlations

Gut Microbiota and Colorectal Cancer: An Umbrella Review of Methodological Trends and Clinical Correlations

Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers

Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis

Contact Info

Product

Resources

About